Valuation
- Market cap
- 2,000
- Revenue TTM
- $0
- Net income TTM
- $-15,530,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 2,000
- Avg volume
- 18,196
- Day's range
- $0.01 – $0.01
- Shares out
- 410,000
- Stochastic %K
- 8%
- Beta
- 0.95
- Analysts
- —
- Price target
- $48.00
Company profile
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, develops immunotherapy products based on its allogeneic gamma delta T cell platform in the United States. Its product pipeline comprises OmnImmune (TCB002), an allogeneic unmodified gamma-delta T cell therapy product which is in phase 2/3 clinical trial for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to tre...
Show more
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, develops immunotherapy products based on its allogeneic gamma delta T cell platform in the United States. Its product pipeline comprises OmnImmune (TCB002), an allogeneic unmodified gamma-delta T cell therapy product which is in phase 2/3 clinical trial for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections, as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 44 14 1433 7557
- Website
- https://tcbiopharm.com
- Address
- Maxim 1, 2 Parklands Way Holytown, Motherwell, United Kingdom
Latest news
No headlines yet.
